Ascendis Pharma A (ASND) Common Equity (2012 - 2026)

Ascendis Pharma A has reported Common Equity for 15 years, with the latest figure at $571.3 million in Q1 2026.

• Quarterly Common Equity rose 386.14% year-over-year to $571.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $571.3 million (up 386.14% YoY) and the FY2025 annual result came in at -$189.5 million, down 107.41% from the prior year.
• Common Equity advanced to $571.3 million in Q1 2026 per ASND's latest filing, from -$189.5 million in the prior quarter.
• Over five years, Common Equity peaked at $2.6 billion in Q4 2024 and troughed at -$345.8 million in Q2 2024.
• A 5-year average of $220.7 million and a median of -$79.9 million in 2023 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 1730.95% in 2024, down 589.79% in 2024.
• Over 5 years, Common Equity stood at $268.7 million in 2022, then plunged by 158.34% to -$156.8 million in 2023, then surged by 1730.95% to $2.6 billion in 2024, then slumped by 107.41% to -$189.5 million in 2025, then soared by 401.42% to $571.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $571.3 million, -$189.5 million, and -$203.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.